131 related articles for article (PubMed ID: 9231061)
21. Immunohistochemistry of pancreatic islet cell tumors in the ferret (Mustela putorius furo).
Andrews GA; Myers NC; Chard-Bergstrom C
Vet Pathol; 1997 Sep; 34(5):387-93. PubMed ID: 9381649
[TBL] [Abstract][Full Text] [Related]
22. Malignant glucagonoma. New options of treatment.
Appetecchia M; Ferretti E; Carducci M; Izzo F; Carpanese L; Marandino F; Terzoli E
J Exp Clin Cancer Res; 2006 Mar; 25(1):135-9. PubMed ID: 16761630
[TBL] [Abstract][Full Text] [Related]
23. Functional studies in patients with the glucagonoma syndrome.
Holst JJ; Helland S; Ingemannson S; Pedersen NB; von Schenck H
Diabetologia; 1979 Sep; 17(3):151-6. PubMed ID: 510830
[TBL] [Abstract][Full Text] [Related]
24. Anaesthetic management of glucagonoma.
Nicoll JM; Catling SJ
Anaesthesia; 1985 Feb; 40(2):152-7. PubMed ID: 2983582
[TBL] [Abstract][Full Text] [Related]
25. Clinical and metabolic aspects of glucagonoma.
Leichter SB
Medicine (Baltimore); 1980 Mar; 59(2):100-13. PubMed ID: 6987481
[TBL] [Abstract][Full Text] [Related]
26. Functional characterization of somatostatin receptors expressed on hamster glucagonoma cells.
Fehmann HC; Strowski M; Göke B
Am J Physiol; 1995 Jan; 268(1 Pt 1):E40-7. PubMed ID: 7840180
[TBL] [Abstract][Full Text] [Related]
27. Glucose inhibits glucagon secretion by a direct effect on mouse pancreatic alpha cells.
Vieira E; Salehi A; Gylfe E
Diabetologia; 2007 Feb; 50(2):370-9. PubMed ID: 17136393
[TBL] [Abstract][Full Text] [Related]
28. A malignant tumor of the pancreas producing glucagonoma syndrome: coexistence of glucagon and pancreatic polypeptide (PP) in the tumor cells.
Bani D; Bani Sacchi T; Biliotti G
Pancreas; 1989; 4(4):511-9. PubMed ID: 2548179
[TBL] [Abstract][Full Text] [Related]
29. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy.
Lamberts SW; Hofland LJ; van Koetsveld PM; Reubi JC; Bruining HA; Bakker WH; Krenning EP
J Clin Endocrinol Metab; 1990 Sep; 71(3):566-74. PubMed ID: 2168430
[TBL] [Abstract][Full Text] [Related]
30. Silent human pancreatic glucagonoma and "A" nesidioblastosis.
Balas D; Senegas-Balas F; Delvaux M; Bertrand C; Fagot-Revurat P; Rumeau JL; Ribet A
Pancreas; 1988; 3(6):734-9. PubMed ID: 2851784
[TBL] [Abstract][Full Text] [Related]
31. Arterial stimulation and venous sampling for glucagonomas of the pancreas.
Eguchi H; Tanemura M; Marubashi S; Kobayashi S; Wada H; Okita K; Iwahashi H; Imagawa A; Shimomura I; Osuga K; Umeshita K; Wakasa K; Mori M; Doki Y; Nagano H
Hepatogastroenterology; 2012; 59(113):276-9. PubMed ID: 21940356
[TBL] [Abstract][Full Text] [Related]
32. Somatostatin analogue in treatment of coexisting glucagonoma and pancreatic pseudocyst: dissociation of responses.
Moattari AR; Cho K; Vinik AI
Surgery; 1990 Sep; 108(3):581-7. PubMed ID: 2168587
[TBL] [Abstract][Full Text] [Related]
33. Effects of pancreastatin on insulin, glucagon and somatostatin secretion by the perfused rat pancreas.
Silvestre RA; Peiró E; Miralles P; Villanueva ML; Marco J
Life Sci; 1988; 42(14):1361-7. PubMed ID: 2895408
[TBL] [Abstract][Full Text] [Related]
34. Somatostatin blockade of acute and chronic stimuli of the endocrine pancreas and the consequences of this blockade on glucose homeostasis.
Chideckel EW; Palmer J; Koerker DJ; Ensinck J; Davidson MB; Goodner CJ
J Clin Invest; 1975 Apr; 55(4):754-62. PubMed ID: 804491
[TBL] [Abstract][Full Text] [Related]
35. Biological activity of somatostatin and somatostatin analogs on inhibtion of arginine-induced insulin and glucagon release in the rat.
Brown M; Rivier J; Vale W
Endocrinology; 1976 Feb; 98(2):336-43. PubMed ID: 813991
[TBL] [Abstract][Full Text] [Related]
36. Effects of rat pancreatic polypeptide on islet-cell secretion in the perfused rat pancreas.
Dégano P; Peiró E; Miralles P; Silvestre RA; Marco J
Metabolism; 1992 Mar; 41(3):306-9. PubMed ID: 1347399
[TBL] [Abstract][Full Text] [Related]
37. In vitro release of vasoactive intestinal polypeptide and pancreatic polypeptide from human VIPoma cells and its inhibition by somatostatin analogue (SMS 201-995).
Yasunami Y; Funakoshi A; Ryu S; Shinozaki H; Jimi A; Miyazaki K; Ikeda S
Surgery; 1994 Jun; 115(6):713-7. PubMed ID: 8197564
[TBL] [Abstract][Full Text] [Related]
38. A case of a giant glucagonoma with parathyroid hormone-related peptide secretion showing an inconsistent postsurgical endocrine status.
Shirai K; Inoue I; Kato J; Maeda H; Moribata K; Shingaki N; Ueda K; Deguchi H; Maekita T; Iguchi M; Yanaoka K; Tamai H; Oka M; Kawai M; Yamaue H; Yasuoka H; Nakamura Y; Iso-O N; Ichinose M
Intern Med; 2011; 50(16):1689-94. PubMed ID: 21841327
[TBL] [Abstract][Full Text] [Related]
39. Influence of glucagon, gastric inhibitory polypeptide, pancreatic polypeptide and somatostatin on beta-adrenergically induced insulin secretion in the mouse.
Ahrén B; Lundquist I
Diabete Metab; 1982 Sep; 8(3):209-12. PubMed ID: 6128264
[TBL] [Abstract][Full Text] [Related]
40. Immunocytochemical characterization of 10 pancreatic tumours, associated with the glucagonoma syndrome, using antibodies to separate regions of the pro-glucagon molecule and other neuroendocrine markers.
Hamid QA; Bishop AE; Sikri KL; Varndell IM; Bloom SR; Polak JM
Histopathology; 1986 Feb; 10(2):119-33. PubMed ID: 3007321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
